SCHEMBL22380050

SCHEMBL22380050

Cc1ccc(-n2cccn2)cc1C(C)C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ MAPT P10636 3/20 0.42
▸ POLB P06746 1/20 0.42
▸ GRM5 P41594 1/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ SOS1 Q07889 1/20 0.39
▸ LRRK2 Q5S007 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ PDK2 Q15119 1/20 0.38
▸ NLRP3 Q96P20 2/20 0.38
▸ KDM5B Q9UGL1 2/20 0.38
▸ CHRNA7 P36544 1/20 0.38
▸ CHRNA10 Q9GZZ6 1/20 0.38
▸ CHRNA9 Q9UGM1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14350201 0.87 NOTUM (0.46) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL18487985 0.83 NOTUM (0.49) NOTUMKDM4EALDH1A1MAPK1POLB
SCHEMBL255913 0.81 NOTUM (0.53) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL22214068 0.79 LMNA (0.46) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL12891749 0.79 KDM5B (0.47) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL14199941 0.79 NOTUM (0.53) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL24012831 0.79 NOTUM (0.41) NOTUMKDM4EALDH1A1MAPK1POLB
SCHEMBL3342462 0.77 NOTUM (0.49) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL11485495 0.77 KDM4E (0.49) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL7027887 0.77 NOTUM (0.49) NOTUMKDM4EALDH1A1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365557-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. (KR) 2023-11-16 — — US disclosed
US-11802126-B2 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders 1ST Biotherapeutics, Inc. (KR) 2023-10-31 — — US disclosed
US-11802126-B2 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders 1ST Biotherapeutics, Inc. (KR) 2023-10-31 — — US disclosed
US-20210347774-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. 2021-11-11 — — US disclosed
US-20200270246-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. 2020-08-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365557-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SMN1; SMN2, SNCA, HTT NOTUM 2836/4885KDM4E 3156/4885ALDH1A1 2344/4885
US-11802126-B2 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders SMN1; SMN2, SNCA, HTT NOTUM 2836/4885KDM4E 3156/4885ALDH1A1 2344/4885
US-20200270246-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SMN1; SMN2, SNCA, HTT NOTUM 2836/4885KDM4E 3156/4885ALDH1A1 2344/4885
US-20210347774-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SMN1; SMN2, SNCA, HTT NOTUM 2836/4885KDM4E 3156/4885ALDH1A1 2344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback